Cell-ing the Future: CytoImmune’s CEO Talks About Expanded Role in Cell Therapy

 

Dr. Jose E Vidal who is currently the CEO of CytoImmune Therapeutics, a company at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials joins eHealth Radio and the Health News and Cancer Information Channels.

Listen to interview with host Eric Michaels and guest Dr. Jose E. Vidal discuss the following:

1. What is gene and cell therapy and how does it work?
2. What conditions can be treated with cell therapy?
3. What is the difference between treatment therapy and curative therapy?
4. What is the difference between chemo/radio therapy and immunotherapy for cancer?
5. When will cell therapy be available to patients? What are the limitations?

In conclusion, cell therapy is the next significant step in fighting hard to treat cancer and autoimmune conditions. It has been proven to provide results superior to any treatment seen before. Now, we are working on improving access for patients by optimizing the manufacturing process and lowering therapy cost.

Dr. Jose Eduardo Vidal obtained his doctoral degree in Cellular and Molecular Biology from the University of Puerto Rico. He started his career in the pharmaceutical industry in Wyeth as a process development scientist working with small molecules and the first Biologics development pipeline upon the acquisition of Immunex.

With Wyeth he worked on the development and commercial launch of Mylotarg (very first ADC). He continued to develop as a biopharmaceutical professional occupying positions of increased responsibility in Tech Services, Process Development and Quality. After 10 years with the company and managing 14 sites world wide Jose joined Amgen as the head of Process Development. With Amgen Jose managed the biologics new product development with over one hundred programs in the pipeline. Jose also managed the drug substance manufacturing organization as the VP of operations and also lead the global late stage product pipeline as the global VP of Process Development where he got acquainted with Cell and Gene therapy.

In 2018 Jose joined Atara where he led the company as SVP of Process Development and Global Quality to develop and submit for commercial licensing the first ever Allogeneic TCell therapy product (Ebvallo) which was approved for commercial distribution in Dec 2022. He also successfully designed and led the development of TCell therapy manufacturing process in stirred tank, perfusion bioreactors.

Lately Jose joined Cytoimmune Therapeutics as the Chief Operations Officer and has been working in starting up the company and the operation from the ground up with operations in PR. Cytoimmune is focused in developing oncology and autoimmune malignancies therapies based on Allogeneic NK-CAR cells.

Jose has also worked with other operations and startups as Pfizer and Biovail and has served as advisor for multiple biotechnology startups with 25 years in the industry in which he has achieved taking from RnD to market more than 200 products/therapies and has pioneered the evolution of therapies from chemical synthesis, biologics to cell and gene therapy. Jose is an early adopter and champion of real time predictive statistical modeling and deep machine learning.

Website: https://www.cytoimmune.com

Social Media Links:
Linkedin: https://www.linkedin.com/company/cytoimmune-therapeutics  
Twitter: @CytoImmune

People also listened to this: A Breakthrough Solution for Treating Central Nervous System Disorders Including Strokes and Cluster Headaches